The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The predictive value of stereotyped BCR subsets in CLL
Thomas Chatzikonstantinou, MD, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses stereotyped B-cell receptor (BCR) subsets in chronic lymphocytic leukemia (CLL), particularly subset two. While subset two has been associated with shorter progression-free survival (PFS) in patients treated with chemotherapy, early data suggest excellent outcomes with targeted therapies like BTK inhibitors (BTKis). Ongoing studies aim to assess the biomarker’s predictive value in fixed-duration treatments. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
